UroAlerts - Prostate Cancer Weekly

April 28, 2026

Videos

Peer-to-Peer Clinical Conversations

Study on Metastatic Hormone-Sensitive Prostate Cancer Survival Trends - Neeraj Agarwal

Neeraj Agarwal

Neeraj Agarwal discusses a Flatiron database analysis examining treatment intensification in metastatic hormone-sensitive prostate cancer.

ctDNA as an Early Response Signal in RLT and mCRPC Care - Alexander Wyatt

Alexander Wyatt

Oliver Sartor hosts Alex Wyatt to discuss the evolving role of circulating tumor DNA (ctDNA) in prostate cancer and how it complements traditional genomic testing used to guide PARP + ARPI treatment selection.

Beyond the Abstracts

Diagnostic Accuracy of Abbreviated Biparametric MRI for Prostate Cancer Screening: A Prospective Feasibility Study (ReIMAGINE Study) - Beyond the Abstract

AI-Driven Body Composition Monitoring and Its Prognostic Role in mCRPC Undergoing Lutetium-177 PSMA Radioligand Therapy: Insights from a Retrospective Single-Center Analysis - Beyond the Abstract

Conference Coverage

PSMA and Beyond 2026: Incorporating PSMA PETs in Registrational Trials

PSMA and Beyond 2026: Modalities for Targeting the Cell Surface

EAU 2026: What Evidence Do We Have from Intensification with SBRT?

ASCO GU 2026: ARTO Trial (NCT03449719): Long-Term Overall Survival Analysis from a Randomized Phase II Trial Testing the Benefit of Stereotactic Body Radiotherapy Addition to Abiraterone Acetate in Oligometastatic CRPC Patients

ASCO GU 2026: Quality of Life, Adherence, and Adverse Events Among Patients with Advanced Prostate Cancer Treated with Relugolix: 6-Month Results of the OPTYX Multicenter Registry

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Post-diagnostic Inflammatory and Insulinemic Diet and Lifestyle Patterns and Risk of Prostate Cancer-Specific Mortality in the Health Professionals Follow-up Study.

Omitting Elective Pelvic Nodes Irradiation in High Risk Prostate Cancer: Report on 43 Consecutive Elderly Patients.

The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review.

Utilization, Cost, and Subsequent Salvage Treatment of Ablative Therapies for Localized Prostate Cancer in the United States.

Canagliflozin Is a Novel Androgen Receptor Pathway Inhibitor for Castrate-Sensitive and Castrate-Resistant Prostate Cancer.

Real-life PI-RADS score and biochemical recurrence after local treatment of prostate cancer in Afro-Caribbean men.

Biophysical membrane responses of hypoxic prostate cancer cells depend on kindlin-2.

Combined radiomics, PI-RADS, and clinical model improve significant prostate cancer prediction and guide biopsy decision.

PRIMA: randomized prospective multicenter non-inferiority study for primary diagnosis of clinically significant PRostate cancer by PSA and MR IMAging-study protocol for a randomized diagnostic accuracy trial.

Polygenic risk score and 20-year prostate cancer-specific mortality and survival.

Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial.

Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).

Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer.

Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients.

Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials.

Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies.

Prognostic Value of [18F]Flotufolastat PET Using Visual RECIP in Docetaxel-Treated Metastatic Prostate Cancer.

PET Imaging of Accessible Prostate-Specific Membrane Antigen Reveals Dose-Dependent and Tumor Burden-Driven Variability.

TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies.

Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study.

Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial.

ProHealth: a co-designed online home-based healthy eating and exercise programme for men with prostate cancer treated with androgen deprivation therapy - a study protocol for a feasibility and preliminary efficacy randomised controlled trial.

Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients.

B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities Across Prostate Cancer Patient Groups.

Disparities in Access to Severe Incontinence Surgical Treatment with Artificial Urinary Sphincter after Radical Prostatectomy in France: A Nationwide Nested Case-control Study.

The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202.

Finding Holes: Pathologist-Level Performance Using AI for Cribriform Morphology Detection in Prostate Cancer.

Trends and Patterns in Prostate Cancer Diagnostics During the Era of MRI Implementation - Real-world Evidence From a Population-based Study in the Stockholm Region, Sweden 2010-2023.

Nodal maximum standardised uptake value improves PSMA-PET/CT-based nodal staging in intermediate- and high-risk prostate cancer.

The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease.

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer - Beyond the Abstract

Targeted and Perilesional or Systematic Biopsies in Prostate Cancer: The TARGET Clinical Trial Protocol - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC